GoAI
Get started
Tectonic Therapeutic, Inc. logo

Tectonic Therapeutic, Inc.

TECX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$37.63

+$1.58 · +4.38%

TECX company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

39

Expensive

Momentum

63

Gaining

Sentiment

61

Bullish

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Alise S. Reicin
Listed since
Jun 21, 2018
Employees
60

Market position

Volume
188.56K
0.93× average
Average volume
203.29K
Average daily volume
Market cap
710.05M USD
Beta
0.22
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
129.69M USD
P/E (TTM)
-8.23×
P/B (TTM)
3.19×
P/S (TTM)
0×
EV / EBITDA
-1.81×
Earnings yield
-19.40%
Free cash flow yield
-15.77%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-29.50%
Return on assets
-28.41%
Return on invested capital
-33.27%

Financial health

Debt / equity
0.02×
Current ratio
26.63×
Altman Z-score
30.64
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−84.04M USD-44.85%

Net income

−74.15M USD-27.89%
Income trends across reported periods−1.42M USD−31.46M USD−61.5M USD−91.55M USDOperating income, FY2021: −15.61M USDOperating income, FY2022: −32.83M USDOperating income, FY2023: −44.65M USDOperating income, FY2024: −58.02M USDOperating income, FY2025: −84.04M USDNet income, FY2021: −8.93M USDNet income, FY2022: −32.18M USDNet income, FY2023: −42.82M USDNet income, FY2024: −57.98M USDNet income, FY2025: −74.15M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −15.61M USD. Operating income FY2022 −32.83M USD. Operating income FY2023 −44.65M USD. Operating income FY2024 −58.02M USD. Operating income FY2025 −84.04M USD. Net income FY2021 −8.93M USD. Net income FY2022 −32.18M USD. Net income FY2023 −42.82M USD. Net income FY2024 −57.98M USD. Net income FY2025 −74.15M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development63.49M USD41.36M USD36.97M USD25.65M USD10.98M USD
Selling, general, and administrative20.55M USD16.65M USD7.68M USD7.18M USD4.63M USD
Operating expenses84.04M USD58.02M USD44.65M USD32.83M USD15.61M USD
Interest income11.3M USD4.26M USD581K USD149K USD—
Interest expense63K USD107K USD152K USD144K USD224K USD
Depreciation and amortization1.38M USD1.65M USD1.48M USD1.01M USD364K USD
Operating income−84.04M USD−58.02M USD−44.65M USD−32.83M USD−15.61M USD
Net income−74.15M USD−57.98M USD−42.82M USD−32.18M USD−8.93M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+1.33%
11 comparable reports
Latest EPS result
-1.18
Estimate -1.35 · Beat by 12.59%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.78-1-1.23-1.45Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.84, estimate -1.39, surprise +39.57%, Beat. Q2 2025, reported May 8, 2025: actual -0.93, estimate -1.1, surprise +15.45%, Beat. Q3 2025, reported Aug 7, 2025: actual -1.07, estimate -0.98, surprise -9.18%, Miss. Q4 2025, reported Nov 6, 2025: actual -1.02, estimate -1.05, surprise +2.86%, Beat. Q1 2026, reported Feb 26, 2026: actual -1.03, estimate -1.11, surprise +7.21%, Beat. Q2 2026, reported May 7, 2026: actual -1.34, estimate -1.16, surprise -15.52%, Miss. Q3 2026, reported Aug 6, 2026: actual -1.18, estimate -1.35, surprise +12.59%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -1.32, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$78.00

107.28% upside
Past 12 months12-month forecastHigh $81.00Average $78.00Low $75.00

TECX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TECX

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
9.55M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.8M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.53M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.61M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.28M
Weight
0.08%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
ALPS Medical Breakthroughs ETF logoALPS Medical Breakthroughs ETFSBIO
Market value
836.33K
Weight
0.35%
AUM
236.37M USD
Expense ratio
0.50%
Price / 1D
$69.11+0.80%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
739.39K
Weight
0.02%
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
718.55K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%

Continue in GoAI

Research TECX

research.disclaimer